Clinical Trial Update: AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial testing AZD6244 (selumetinib) in combination with docetaxel versus docetaxel alone in KRAS-mutant non-small cell lung cancer has completed, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• selumetinib (AZD6244) (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-06-20